RecruitingNCT03291028

Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

Defining the Genomic and Histologic Landscape of Primary and Metastatic Tumors With Divergent Kinetics in Patients With Renal Cell Carcinoma (RCC) and Urothelial Carcinoma (UC) Treated With Immune Checkpoint Blockade (ICB)

Sponsor

Fox Chase Cancer Center

Enrollment

16 participants

Start Date

Nov 27, 2017

Study Type

OBSERVATIONAL

Conditions

Urothelial Carcinoma Renal Cell Carcinoma Bladder Cancer Ureter Cancer Urethral Cancer

Summary

This is a comparative study using resected/ biopsied tumors samples collected from renal cell carcinoma and urothelial carcinoma patients who underwent surgical removal of lesions, followed by immune checkpoint blockade (ICB) treatment targting programmed cell death 1 (PD1) but developed new lesions later were also removed and stored in the biosample repository (BSR). The histology and genomic analysis of the pre-treatment and metastatic samples from the same patient would be used to find out the changes that may have lead to metastasis. Also, metastatic samples from ICB naive patients would be collected and compared with those from ICB treated patients to find out if the metastasis in treated patients was due to development of reistance.

Eligibility

Plain Language Summary

Simplified for easier understanding

This study is analyzing tumor tissue — from both the original tumor and from new lesions that appeared later — in patients with kidney cancer or bladder/urinary tract cancer, to understand why some tumors develop resistance to immunotherapy drugs over time. **You may be eligible if...** - You have kidney cancer (renal cell carcinoma) or urinary tract cancer (urothelial carcinoma) - You previously responded to immunotherapy (checkpoint blocker treatment), but then developed a new or growing isolated tumor lesion that was surgically removed - OR you have kidney cancer and had surgery to remove a spread (metastatic) lesion without having received immunotherapy (to serve as a comparison group) **You may NOT be eligible if...** - There are no specific exclusion criteria listed beyond the basic description above Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALImmune checkpoint inhibitor targeting PD1

RCC and UC patients treated with immune checkpoint blockade

Locations(1)

Fox Chase Cancer Center - Philadelphia

Philadelphia, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03291028

Related Trials

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

NCT0498150913 locations

En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device

NCT042357641 location

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

NCT000268841 location

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

NCT07129993100 locations

Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers

NCT069679611 location